MHRA (UK)Original article
Continuous renal replacement therapy (CRRT): Consider delayed administration of concurrent echinocandins, such as caspofungin, to reduce the risk of adsorption onto new polyacrylonitrile (PAN)-based filter membranes DSI/2026/014
RegulatorycaspofunginNegative
AI Analysis
Summary
The MHRA issued guidance recommending delayed administration of caspofungin during continuous renal replacement therapy with PAN-based filter membranes to reduce adsorption and maintain antifungal efficacy.
Importance:3/10
Sentiment:
-0.30
drug safetyCRRTadsorption riskregulatory guidanceantifungalpolyacrylonitrile membrane
Read the original article
Published by MHRA (UK) on October 13, 2026 11:38 AM